Crescita Therapeutics Reports Fourth Quarter and Fiscal 2018 Results Record Annual Revenue of $16.6M and Adjusted EBITDA of $1.5M Strong Royalties and Sales Milestones

Stock Information for Crescita Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Crescita Therapeutics Inc.

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Crescita Therapeutics Reports 2019 First Quarter Results
Crescita Therapeutics Strengthens Leadership Team with New Vice-President in Aesthetic and Cosmeceutical Business Unit
Crescita Therapeutics Signs Pliaglis® Out-Licensing Agreement with Cantabria Labs for Euro2.5M Upfront After Reacquiring Rest-of-World Rights
Crescita Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference in Toronto
Crescita Therapeutics Inc.(TM) and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra's Dermatology Product Portfolio
U.S. FDA Approves Removal of "Not for Home Use" Label Restriction for Pliaglis®
Crescita Therapeutics(TM) Reports 2018 Third Quarter Results Strong Royalty Revenue and Achievement of First Pliaglis US Sales Milestone Positive Adjusted EBITDA of $0.8M

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.